Latanoprostene bunod ophthalmic solution 0.024% brings a novel mechanism of action for IOP lowering and is proving to be a useful addition for patient care.
Reviewed by Andrew G. Iwach, MD
Latanopostene bunod ophthalmic solution 0.024% (LBN) (Vyzulta, Bausch + Lomb) is a safe and effective addition to the IOP-lowering treatment armamentarium, and seems to offer particular value for managing patients who do not respond adequately to traditional firstline therapy, including those with a lower initial IOP, said Andrew G. Iwach, MD.
“The introduction of latanoprost more than two decades ago dramatically changed management for patients with elevated IOP and because of its effectiveness, greatly helped reduce the need for glaucoma surgery,” said Dr. Iwach, executive director, Glaucoma Center of San Francisco, and co-founder, Eye Surgery Center of San Francisco, San Francisco.
“Compared with latanoprost, LBN provides a potential additional mechanism of action for IOP-lowering that explains why it may be even more effective and have a particular benefit in certain patients,” Dr. Iwach said.
Latanoprostene bunod is a nitric oxide (NO)- donating prostanoid FP receptor agonist that is metabolized in the eye into two moieties—the F2a prostaglandin analog, latanoprost acid, and butanediol mononitrate from which NO is released.
Andrew G. Iwach, MD
E: [email protected]
Dr. Iwach is a consultant to and on the speakers’ bureau for Bausch + Lomb.